Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446659 | 0.97 | FFAR4 (0.42) | FFAR4FFAR1NR1H2NR1H3HRH1 | |
| SCHEMBL2447449 | 0.93 | NR1H2 (0.42) | FFAR4FFAR1NR1H2NR1H3 | |
| SCHEMBL2446352 | 0.91 | NR1H2 (0.41) | FFAR4FFAR1NR1H2NR1H3 | |
| SCHEMBL3508725 | 0.91 | NR1H2 (0.46) | FFAR4FFAR1NR1H2NR1H3 | |
| SCHEMBL3508439 | 0.90 | NR1H2 (0.44) | FFAR4FFAR1NR1H2NR1H3 | |
| SCHEMBL2446559 | 0.90 | NR1H2 (0.42) | NR1H2NR1H3 | |
| SCHEMBL2452781 | 0.89 | NR1H2 (0.44) | NR1H2NR1H3 | |
| SCHEMBL2450254 | 0.89 | NR1H2 (0.42) | NR1H2NR1H3 | |
| SCHEMBL2451408 | 0.89 | NR1H2 (0.51) | FFAR4FFAR1NR1H2NR1H3 | |
| SCHEMBL3632890 | 0.87 | NR1H2 (0.45) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367801-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | Wyeth LLC (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | FFAR4 59/4885FFAR1 52/4885NR1H2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.